MaxCyte is maintaining its leading position in the field of flow electroporation, an enabling technique for many advanced cell therapies. There are now over 45 cell therapies in development that use MaxCyte's proprietary technologies, and data published so far this year continue to highlight the utility of MaxCyte's instruments. The company signed a commercial licensing deal in March, and many more could be signed in the coming years. For a number of reasons revenue growth slowed to 13.5% in H117, but we expect significantly stronger growth in H217. We maintain our valuation at £178m, or 351p per share.
13 Jul 2017
Consolidating its leadership
Sign up for free to access
Get access to the latest equity research in real-time from 12 commissioned providers.
Get access to the latest equity research in real-time from 12 commissioned providers.
Consolidating its leadership
MaxCyte, Inc. (MXCT:LON) | 345 0 0.0% | Mkt Cap: 359.2m
- Published:
13 Jul 2017 -
Author:
Mick Cooper PhD -
Pages:
3
MaxCyte is maintaining its leading position in the field of flow electroporation, an enabling technique for many advanced cell therapies. There are now over 45 cell therapies in development that use MaxCyte's proprietary technologies, and data published so far this year continue to highlight the utility of MaxCyte's instruments. The company signed a commercial licensing deal in March, and many more could be signed in the coming years. For a number of reasons revenue growth slowed to 13.5% in H117, but we expect significantly stronger growth in H217. We maintain our valuation at £178m, or 351p per share.